The Quantellect read.As of Nov 19, 2026, 7 active firms cover Zevra Therapeutics Inc: 7 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets span $20.00 to $35.00, a moderate spread. The average target of $27.14 sits 193% above the current $9.27. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.20 next quarter toward $0.89 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS7 active firms
Buy
Strong Buy00%
Buy7100%
Neutral00%
Sell00%
Strong Sell00%
Based on 7 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$27.14
+192.8% upside
Average target across 7 active firms as of Nov 19, 2026 vs $9.27 current
Highest Target$35.00
Average Target$27.14
Lowest Target$20.00
Detailed analyst forecasts for ZVRA
Showing 1–8 of 8 named analysts shown · 7 active firms in the rating projection
As of Nov 19, 2026, 7 of 7 active firms rate ZVRA a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
ZVRA EPS & revenue forecast
EPS · NEXT QUARTER
$0.20
Range $0.15 – $0.27 · 3 analysts · +13% YoY
Next period, 3 analysts expect Zevra Therapeutics Inc. to earn $0.20 a share (range $0.15 – $0.27), versus $0.18 a year earlier. Full-year consensus is $1.27, growing to $0.89 the year after.
REVENUE · NEXT QUARTER
$38.8M
Range $33.9M – $41.8M · 3 analysts · +7% YoY
Revenue is expected to reach $38.8M (range $33.9M – $41.8M), +7.2% year-over-year. Full-year consensus is $153.1M, rising to $176.5M next year.
Top analysts covering Zevra Therapeutics Inc.
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ZVRA.
#1
Jason Butler
JMP Securities · Rank #62
Buy
$28.00+202.0% to target
Overall win rate
49%
+ Follow
#2
Oren Livnat
HC Wainwright & Co. · Rank #217
Buy
$20.00+115.7% to target
Overall win rate
54%
+ Follow
#3
Kristen Kluska
Cantor Fitzgerald · Rank #232
Buy
$25.00+169.7% to target
Overall win rate
38%
+ Follow
#4
BF
Brandon Folkes
HC Wainwright & Co. · Rank #402
Buy
$26.00+180.5% to target
Overall win rate
38%
+ Follow
#5
Sumant Kulkarni
Canaccord Genuity · Rank #419
Buy
$20.00+115.7% to target
Overall win rate
39%
+ Follow
ZVRA stock forecast FAQ
What is ZVRA's average 12-month price target?+
The 7 active firms with a live target average $27.14 for Zevra Therapeutics Inc. over the next 12 months, ranging from a $35.00 high to a $20.00 low, as of Nov 19, 2026.
Is ZVRA stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 7 active firms as of Nov 19, 2026, 7 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for ZVRA?+
The Street-high target is $35.00 (Maxim Group), and the Street-low is $20.00 (Canaccord Genuity). The average of all 7 active-firm targets is $27.14.
How many active Wall Street firms cover ZVRA?+
7 active firms have a recognized rating on Zevra Therapeutics Inc. as of Nov 19, 2026, and 7 active firms carry a live 12-month price target.
Who is the most accurate analyst covering ZVRA?+
Among analysts who currently cover ZVRA, Jason Butler of JMP Securities has the strongest overall Quantellect track record (Rank #62). Their current call is Buy with a $28.00 target.
What is Zevra Therapeutics Inc.'s projected EPS for next quarter?+
The consensus estimate is $0.20 per share (range $0.15 – $0.27) across 3 analysts. Full-year EPS is projected at $1.27, rising to $0.89 the following year.
How much revenue is Zevra Therapeutics Inc. expected to report next quarter?+
Consensus revenue is $38.8M (range $33.9M – $41.8M). Full-year revenue is projected at $153.1M, growing to $176.5M next year.
Have analysts been upgrading or downgrading ZVRA lately?+
As of Nov 19, 2026, 7 of 7 active firms rate ZVRA a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ZVRA calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.